Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure

NCT ID: NCT05591443

Last Updated: 2022-10-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-31

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart failure is the major pandemic of the 21st century. The number of patients and of Heart Failure-related deaths is progressively increasing. This means a devastating economic and health organization burden. In fact, chronic heart failure patients are at high risk of death, and the course of the disease is often insidious and uncertain with a progressive deterioration requiring the need for repeated and successive hospitalizations with an ominous prognosis: with each admission for acute heart failure there is a short-term improvement, a phase characterized by a degree of stability, and then a worsening phase follows until a new need for a new hospitalization. Moreover, with each subsequent hospitalization, myocardial function progressively declines, gradually worsening the patient's quality of life until the fatal event.

For these reasons, one of the major unmet needs is the identification of patients with a negative trajectory of Heart Failure. Accordingly, early identification of Heart Failure worsening is mandatory to improve patient condition and reduce Heart Failure costs, which are mainly associated with hospitalizations.

Our main goal through this project is to create clinical tool for detection of early signs of chronic heart failure (CHF) worsening that will allow timely therapeutic intervention. This timely manner intervention can lead to a much better outcome for the patient, possibly reducing the need for hospitalization or lower the number of hospitalization days.

The aim of this project is to develop clinical decision tool based on artificial intelligence (AI) algorithms to early detect the signs of exacerbation of chronic heart failure and predict the risk of its progression, by integrating high quality medical data obtained through a wearable device (L.I.F.E. Italia Srl's "wearable clinic" - a vest with accessories, which is a TRL 9 medical grade sensorized garment, already available on the market). Specifically, the focus will be on the early detection of CHF worsening in patients who have already been diagnosed with CHF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure,Congestive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heart failure patients

Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of symptoms and/or signs of HF
* left ventricular ejection fraction (LVEF) ≤40%. LVEF values will be obtained by determining the reduced LV systolic function, by transthoracic echocardiographic assessment as recommended by European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography position paper.
* NYHA functional classes II-III).

Exclusion Criteria

* NYHA functional class IV,
* Candidates for left-ventricular assist device (LVAD) or heart transplant, as per latest definition of Heart Failure Association of the ESC.
* Recent acute coronary syndrome within 1-year prior to the date of potential enrollment,
* Indirect echocardiographic evidence of significantly elevated pulmonary pressures
* Clinically relevant pulmonary hypertension
* non-adherence to optimal medical treatment for CHF
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro Cardiologico Monzino

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Piergiuseppe Agostoni

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Piergiuseppe Agostoni, Prof

Role: CONTACT

0258002010

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

weHeartClinic

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mobile App for Heart Failure
NCT05668000 COMPLETED NA
Drug Management in Heart Failure
NCT06915584 RECRUITING